Results | Latest & Breaking News on Results | Photos, Videos, Breaking Stories and Articles on Results

you are here: Home News

Dr Reddy's Labs Q3 Preview: Lower Revlimid contribution, subdued US sales to dent earnings growth
Dr Reddys Laboratories Q1 PAT seen up 73.7% YoY to Rs 912.4 cr: Nirmal Bang
Dr Reddy’s Q3 Preview | Sharp drop in net profit likely on slump in US revenues
Dr Reddy’s Q2 preview: Pharma major likely to report sharp drop in net profit on weak US biz
Dr Reddy’s Q1 Results Preview | Profit may rise 47-50%; revenue likely to grow 11-12%
Dr Reddys Q1 PAT seen up 65.5% YoY to Rs 629.9 cr: ICICI Direct
Dr Reddys Laboratories Q1 PAT seen up 15.9% YoY to Rs 661.8 cr: Prabhudas Lilladher
Dr Reddy’s Q3 Preview | Revenue expected to increase 10-15%, PAT likely to grow 22-25%
Dr. Reddy’s Laboratories Q2 PAT may dip 11.5% YoY to Rs 752.2 cr: Prabhudas Lilladher
Dr. Reddy’s Laboratories Q1 PAT seen up 10.2% YoY to Rs 655.4 cr: KRChoksey
Dr Reddy’s Q1 PAT seen up 5.4% YoY to Rs 626.7 cr: ICICI Direct
Dr Reddy's Labs to announce Q4 numbers today, here's what brokerages expect
Dr Reddy’s Lab Q4 PAT may dip 13.6% YoY to Rs. 674.5 cr: Sharekhan
Dr Reddy's Labs Q3 preview: YoY rise in sales, profit expected; updates on niche ANDA filings, new launches to be in focus
Dr. Reddy’s Lab Q3 PAT to Rs. 729.7 cr: Yash Securities
Dr. Reddy’s Laboratories Q3 PAT may dip 2% YoY to Rs. 781.6 cr: Prabhudas Lilladher
Dr Reddy's Labs Q1 Preview: Profit may decline on higher base, but revenue can grow over 5%
Dr Reddy's Labs reports strong operating performance in Q3: Key highlights from concall
Dr Reddy's hits over 3-year high as analysts remain positive, raise target post Q3 show
Dr. Reddy’s Q2 PAT may dip 10% YoY to Rs. 455.9 cr: Emkay
Dr. Reddy’s Laboratories Q1 PAT seen up 13.6% YoY to Rs. 540.8 cr: Prabhudas Lilladher
Dr Reddy's Q4 preview: Profit to rise 37% YoY to Rs 413cr; EBITDA margin may touch 23%
Dr Reddy’s Laboratories Q4 PAT seen up 36.9% YoY to Rs. 413.6 cr: Kotak
Dr. Reddy’s Laboratories Q4 PAT seen up 88.4% YoY to Rs. 512.7 cr: Prabhudas Lilladher
Dr Reddy's climbs 3% even as analysts view on Q3 earnings mixed

English

Markets

News

Personal Finance

Mutual Funds

Commodities

Media

Invest Now

Specials

Dr Reddy's Labs Q3 Preview: Lower Revlimid contribution, subdued US sales to dent earnings growth

Dr Reddys Laboratories Q1 PAT seen up 73.7% YoY to Rs 912.4 cr: Nirmal Bang

Dr Reddy’s Q3 Preview | Sharp drop in net profit likely on slump in US revenues

Dr Reddy’s Q2 preview: Pharma major likely to report sharp drop in net profit on weak US biz

Dr Reddy’s Q1 Results Preview | Profit may rise 47-50%; revenue likely to grow 11-12%

Dr Reddys Q1 PAT seen up 65.5% YoY to Rs 629.9 cr: ICICI Direct

Dr Reddys Laboratories Q1 PAT seen up 15.9% YoY to Rs 661.8 cr: Prabhudas Lilladher

Dr Reddy’s Q3 Preview | Revenue expected to increase 10-15%, PAT likely to grow 22-25%

Dr. Reddy’s Laboratories Q2 PAT may dip 11.5% YoY to Rs 752.2 cr: Prabhudas Lilladher

Dr. Reddy’s Laboratories Q1 PAT seen up 10.2% YoY to Rs 655.4 cr: KRChoksey

Dr Reddy’s Q1 PAT seen up 5.4% YoY to Rs 626.7 cr: ICICI Direct

Dr Reddy's Labs to announce Q4 numbers today, here's what brokerages expect

Dr Reddy’s Lab Q4 PAT may dip 13.6% YoY to Rs. 674.5 cr: Sharekhan

Dr Reddy's Labs Q3 preview: YoY rise in sales, profit expected; updates on niche ANDA filings, new launches to be in focus

Dr. Reddy’s Lab Q3 PAT to Rs. 729.7 cr: Yash Securities

Dr. Reddy’s Laboratories Q3 PAT may dip 2% YoY to Rs. 781.6 cr: Prabhudas Lilladher

Dr Reddy's Labs Q1 Preview: Profit may decline on higher base, but revenue can grow over 5%

Dr Reddy's Labs reports strong operating performance in Q3: Key highlights from concall

Dr Reddy's hits over 3-year high as analysts remain positive, raise target post Q3 show

Dr. Reddy’s Q2 PAT may dip 10% YoY to Rs. 455.9 cr: Emkay

Dr. Reddy’s Laboratories Q1 PAT seen up 13.6% YoY to Rs. 540.8 cr: Prabhudas Lilladher

Dr Reddy's Q4 preview: Profit to rise 37% YoY to Rs 413cr; EBITDA margin may touch 23%

Dr Reddy’s Laboratories Q4 PAT seen up 36.9% YoY to Rs. 413.6 cr: Kotak

Dr. Reddy’s Laboratories Q4 PAT seen up 88.4% YoY to Rs. 512.7 cr: Prabhudas Lilladher

Dr Reddy's climbs 3% even as analysts view on Q3 earnings mixed